SEC Filing Summary: Hemispherx Biopharma, Inc. (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Hemispherx Biopharma, Inc. on May 28, 2010. The report discloses the entry into a material definitive agreement regarding an equity distribution program. Note: The request metadata references "AIM Immunotech Inc.," but the filing text explicitly identifies the registrant as Hemispherx Biopharma, Inc.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity figures. The document focuses exclusively on the terms of a new equity distribution agreement.
Material Changes and Agreements
On May 28, 2010, the Company entered into an Equity Distribution Agreement with Maxim Group LLC to establish an "at-the-market" equity program. Key terms include:
- Shares Authorized: Up to 32,000,000 shares of common stock may be sold.
- Commission Structure: Maxim Group LLC will receive a 4.0% commission on gross sales up to $10,000,000 in aggregate proceeds, and 3.0% on sales thereafter.
- Sales Method: Sales may be made via ordinary brokers' transactions, including on the NYSE Amex, at prevailing market prices.
- Flexibility: The Company has no obligation to sell any shares and may suspend or terminate the agreement at any time.
Guidance, Outlook, and Risks
The filing contains no management guidance, financial outlook, or discussion of operational risks. The primary contingency noted is that the Company is not obligated to sell any shares under the agreement. The offering is subject to the effectiveness of a previously filed Registration Statement on Form S-3 (File No. 333-159856).
Investor Verification Checklist
- Verify the current share count and potential dilution impact of selling up to 32,000,000 shares.
- Review the filed Prospectus Supplement (dated May 28, 2010) for specific use of proceeds.
- Monitor future 8-K filings or quarterly reports for actual sales volume and proceeds generated under this agreement.
- Confirm the current status of the Form S-3 Registration Statement (File No. 333-159856).